Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by (c) Vieira, Raquel et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/166338

Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed

Citació

Citació

VIEIRA, Raquel, SOUTO, Selma b., SÁNCHEZ-LÓPEZ, E. (elena), LÓPEZ-MACHADO, Ana, SEVERINO, Patrícia, JOSE, Sajan, SANTINI, Antonello, FORTIUNA, Ana, GARCÍA LÓPEZ, María luisa, SILVA, Amélia m., SOUTO, Eliana b.. Sugar-lowering drugs for type 2 Diabetes Mellitus and Metabolic Syndrome Review of cassical and new compounds: Part-I. _Pharmaceuticals_. 2019. Vol. 12, núm. 4, pàgs. 152. [consulta: 15 de gener de 2026]. ISSN: 1424-8247. [Disponible a: https://hdl.handle.net/2445/166338]

Exportar metadades

JSON - METS

Compartir registre